BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack) vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack)
The complete healing triad combining the Wolverine Stack with GHK-Cu (copper peptide) for comprehensive tissue repair. This blend addresses healing at multiple levels: cellular repair, collagen synthesis, and tissue regeneration.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack) | Exenatide |
|---|---|---|
| Mechanism | BPC-157 promotes angiogenesis and growth factor expression. TB-500 enhances cell migration and reduces inflammation. GHK-Cu activates genes involved in tissue remodeling, stimulates collagen and elastin production, and provides antioxidant protection. Together they support healing from multiple angles. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Typical protocol: BPC-157 250-500mcg daily, TB-500 2-2.5mg twice weekly, GHK-Cu 1-2mg daily or applied topically for skin applications. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | BPC-157 and TB-500 via subcutaneous injection. GHK-Cu can be injected subcutaneously or used topically depending on the target area. Systemic and local administration may be combined. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Generally well-tolerated. Possible injection site irritation, mild fatigue, or temporary skin discoloration with GHK-Cu. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |